WO2002047726A3 - Pharmaceutical composition containing an active with a hemolytic action and a surfactant - Google Patents

Pharmaceutical composition containing an active with a hemolytic action and a surfactant Download PDF

Info

Publication number
WO2002047726A3
WO2002047726A3 PCT/JP2001/010809 JP0110809W WO0247726A3 WO 2002047726 A3 WO2002047726 A3 WO 2002047726A3 JP 0110809 W JP0110809 W JP 0110809W WO 0247726 A3 WO0247726 A3 WO 0247726A3
Authority
WO
WIPO (PCT)
Prior art keywords
surfactant
pharmaceutical composition
active
composition containing
hemolytic action
Prior art date
Application number
PCT/JP2001/010809
Other languages
French (fr)
Other versions
WO2002047726A2 (en
Inventor
Kiyoyasu Mizutani
Hirofumi Yamane
Noburu Negishi
Original Assignee
Japan Tobacco Inc
Kiyoyasu Mizutani
Hirofumi Yamane
Noburu Negishi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc, Kiyoyasu Mizutani, Hirofumi Yamane, Noburu Negishi filed Critical Japan Tobacco Inc
Priority to AU2002218535A priority Critical patent/AU2002218535A1/en
Priority to AU2002218535A priority patent/AU2002218535A8/en
Publication of WO2002047726A2 publication Critical patent/WO2002047726A2/en
Publication of WO2002047726A3 publication Critical patent/WO2002047726A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention provides a pharmaceutical composition, which comprises a pharmacologically active ingredient having hemolytic action, a surfactant and an additional additive which can enhance the hemolysis suppression ability of the surfactant.
PCT/JP2001/010809 2000-12-12 2001-12-10 Pharmaceutical composition containing an active with a hemolytic action and a surfactant WO2002047726A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002218535A AU2002218535A1 (en) 2000-12-12 2001-12-10 Pharmaceutical composition containing an active with a hemolytic action and a surfactant
AU2002218535A AU2002218535A8 (en) 2000-12-12 2001-12-10 Pharmaceutical composition containing an active with a hemolytic action and a surfactant

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000378016 2000-12-12
JP2000-378016 2000-12-12

Publications (2)

Publication Number Publication Date
WO2002047726A2 WO2002047726A2 (en) 2002-06-20
WO2002047726A3 true WO2002047726A3 (en) 2007-11-22

Family

ID=18846659

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/010809 WO2002047726A2 (en) 2000-12-12 2001-12-10 Pharmaceutical composition containing an active with a hemolytic action and a surfactant

Country Status (3)

Country Link
JP (1) JP2002241311A (en)
AU (2) AU2002218535A1 (en)
WO (1) WO2002047726A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347824B4 (en) * 2003-10-10 2011-08-11 Lach, Hans-Joachim, Dr., 79331 Pharmaceutical or cosmetic composition for the treatment of the skin
JP2012017308A (en) * 2010-07-09 2012-01-26 Nipro Corp Gemcitabine aqueous solution formulation

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784692A (en) * 1967-06-16 1974-01-08 Warner Lambert Co 17-propionate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
US4318864A (en) * 1979-12-17 1982-03-09 American Cyanamid Company Process for making s-phenenyltris(sulfonylimino)tri-benzene mono- and di-sulfonic acids and salts
JPS60166610A (en) * 1984-02-09 1985-08-29 Fujisawa Pharmaceut Co Ltd Emulsion composition
JPH09124478A (en) * 1995-11-02 1997-05-13 Nippon Zenyaku Kogyo Kk Agent for injection to be applied to livestock with vitamin e and selenium deficiency
WO1999010008A1 (en) * 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US5880123A (en) * 1994-12-23 1999-03-09 Merck Sharp & Dohme Limited Hemolysis prevention by non-ionic surfactants
WO1999041416A2 (en) * 1998-02-17 1999-08-19 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
WO1999048492A1 (en) * 1998-03-26 1999-09-30 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3784692A (en) * 1967-06-16 1974-01-08 Warner Lambert Co 17-propionate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use
US4318864A (en) * 1979-12-17 1982-03-09 American Cyanamid Company Process for making s-phenenyltris(sulfonylimino)tri-benzene mono- and di-sulfonic acids and salts
JPS60166610A (en) * 1984-02-09 1985-08-29 Fujisawa Pharmaceut Co Ltd Emulsion composition
US5880123A (en) * 1994-12-23 1999-03-09 Merck Sharp & Dohme Limited Hemolysis prevention by non-ionic surfactants
JPH09124478A (en) * 1995-11-02 1997-05-13 Nippon Zenyaku Kogyo Kk Agent for injection to be applied to livestock with vitamin e and selenium deficiency
WO1999010008A1 (en) * 1997-08-29 1999-03-04 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
WO1999041416A2 (en) * 1998-02-17 1999-08-19 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
WO1999048492A1 (en) * 1998-03-26 1999-09-30 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
EP1072263A1 (en) * 1998-03-26 2001-01-31 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KAMIICHI, TOKU ET AL: "Injectable preparations causing no hemolysis for treatment of vitamin E- and selenium-deficiency in livestock", XP002207207, retrieved from STN Database accession no. 127:70863 HCA *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; UEDA, YOSHIO ET AL: "Pharmacentical emulsions", XP002207206, retrieved from STN Database accession no. 104:39731 HCA *
DATABASE WPI Section Ch Week 199729, Derwent World Patents Index; Class A96, AN 1997-316474, XP002207208 *

Also Published As

Publication number Publication date
JP2002241311A (en) 2002-08-28
AU2002218535A1 (en) 2002-06-24
WO2002047726A2 (en) 2002-06-20
AU2002218535A8 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
YU73503A (en) Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
WO2005009381A3 (en) Immediate-release formulation of acid-labile pharmaceutical compositions
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
WO2002051424A8 (en) Drugs against articular failure
WO2000041681A3 (en) MEDICINAL FORMULATIONS CONTAINING AN OPIOID AND AN α-ANTAGONIST
AU2000279625A1 (en) Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
AU2002253619A1 (en) Heterocyclic compound and antitumor agent containing the same active ingredients
WO2005045689A8 (en) Methods and systems for network coordination
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
EG23228A (en) Active compound combinations having insecticidal and acaricidal properties.
WO2001068092A3 (en) Glycogen phosphorylase inhibitor
AU2001266075A1 (en) Combinations of active ingredients, which exhibit insecticidal and acaricidal properties
WO2001072125A8 (en) Active substance combinations having insecticidal and acaricidal properties
EP1295879A4 (en) Medicinal compositions containing propenone derivatives
WO2002048142A1 (en) Medicinal compositions having improved absorbability
AU2001268131A1 (en) Stabilized compositions containing oxygen-labile active agents
WO2005065639A3 (en) Novel pharmaceutical compositions
WO2003035686A3 (en) Compositions of fsh with high sialylation degree and their use for the preparation of medicaments
WO2001078682A3 (en) Sustained release drug compositions
EP1607097A3 (en) Stabilized compositions containing an oxygen-labile agent
WO2005065047A3 (en) Stable oral composition containing desloratadine
WO2002047726A3 (en) Pharmaceutical composition containing an active with a hemolytic action and a surfactant
WO2004064517A3 (en) Termiticide compositions
EP1550667A4 (en) Tyrosinase activity controlling agents, process for producing the same and external preparations containing the same
WO2002042367A3 (en) Fluorinated amino polyhedral borate compounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AU AZ BA BB BG BR BY BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS KG KR KZ LC LK LR LT LV MA MD MG MK MN MX NO NZ OM PH PL RO RU SG SI SK TJ TM TN TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase